RecruitingNot ApplicableNCT06807502
Evaluation of Circulating Tumor Cells (CTC) Relevance in Breast Cancer Follow-up Using the ScreenCell Device
Sponsor
ScreenCell
Enrollment
93 participants
Start Date
Feb 24, 2025
Study Type
INTERVENTIONAL
Summary
Liquid biopsy is a noninvasive method for detecting and quantifying circulating tumor cells (CTCs). Thanks to ScreenCell technology, this study aims to evaluate the evolution of the number of CTCs during breast cancer follow-up. The identification and characterization of CTCs would make it possible to obtain information on the stage and molecular characteristics of cancer during follow-up
Eligibility
Sex: FEMALEMin Age: 18 Years
Inclusion Criteria9
- For all participants :
- Age greater than or equal to 18 years
- For participants with metastatic breast cancer:
- \- Patient observed with metastatic breast cancer from the outset or metastatic fall from previously treated breast cancer with change of therapeutic line at the time of inclusion.
- For participants with non-metastatic invasive breast cancer:
- \- Patient observed with non-metastatic infiltrative breast cancer who had not received any treatment at the time of inclusion (naïve to any treatment)
- For healthy volunteers:
- Participant free of any cancer at the time of inclusion, confirmed using a mammogram whose results must be satisfactory, done at the latest one year before inclusion
- Participant with no history of cancer
Exclusion Criteria10
- For all participants:
- Age less than 18 years old
- Refusal to participate or withdrawal of consent
- Pregnant and/or breastfeeding women
- Discovery of a cancerous pathology (other than breast cancer for patients) during participant follow-up.
- For participants with breast cancer:
- \- Absence of CTC during screening
- For healthy volunteers:
- History of cancer
- Detection of CTC (positive profile) during screening
Interventions
DEVICEThe DM/DIV ScreenCell is the experimental product studied during this research
The product is not used directly on the subject, but on a blood sample taken from the participant.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06807502